Drug Trial Radar · NCT05717920
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Feb 15, 2023
Primary completion
Nov 21, 2023
Study completion Nov 21, 2023
Sponsor
- Lead sponsor
- Aldeyra Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
Conditions
- Atopic Dermatitis
Interventions
ADX-629 (Open-label)Drug
ADX-629 (250 mg) administered twice daily for 90 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Serious Adverse EventsTime frame: The safety assessment period was approximately 15 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bexley Dermatology Research
Bexley, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.